BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 15095096)

  • 21. Serum levels of soluble vascular endothelial growth factor receptor-2 in patients with systemic sclerosis.
    Jinnin M; Makino T; Kajihara I; Honda N; Makino K; Ogata A; Ihn H
    Br J Dermatol; 2010 Apr; 162(4):751-8. PubMed ID: 19886888
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum MMP-1 and TIMP-1 levels are increased in patients with psoriatic arthritis and their siblings.
    Myers A; Lakey R; Cawston TE; Kay LJ; Walker DJ
    Rheumatology (Oxford); 2004 Mar; 43(3):272-6. PubMed ID: 14523226
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-cyclic citrullinated peptide antibodies and IL-23p19 in psoriatic arthritis.
    Shibata S; Tada Y; Komine M; Hattori N; Osame S; Kanda N; Watanabe S; Saeki H; Tamaki K
    J Dermatol Sci; 2009 Jan; 53(1):34-9. PubMed ID: 18752933
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Correlations between serum matrix metalloproteinase (MMP-1, MMP-3, MMP-9, MMP-13) concentrations and markers of disease activity in early rheumatoid arthritis].
    Fiedorczyk M; Klimiuk PA; Sierakowski S; Domysławska I; Chwiećko J
    Przegl Lek; 2005; 62(12):1321-4. PubMed ID: 16786739
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [A basic study of determination matrix metalloproteinase-3 and carbohydrate in rheumatoid factor in serum for diagnosis of rheumatoid arthritis].
    Urata M; Nakamura N; Kinoshita S; Kayamori Y; Hamasaki N
    Rinsho Byori; 2003 Aug; 51(8):745-50. PubMed ID: 13677934
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased serum pentraxin 3 in patients with systemic sclerosis.
    Iwata Y; Yoshizaki A; Ogawa F; Komura K; Hara T; Muroi E; Takenaka M; Shimizu K; Hasegawa M; Fujimoto M; Takehara K; Sato S
    J Rheumatol; 2009 May; 36(5):976-83. PubMed ID: 19273457
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-DNA topoisomerase II alpha autoantibodies in Japanese patients with systemic sclerosis.
    Hayakawa I; Hasegawa M; Takehara K; Sato S
    Arch Dermatol Res; 2005 Oct; 297(4):180-3. PubMed ID: 16180014
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Matrix metalloproteinase-3 serum levels are correlated with disease activity and predict clinical response in rheumatoid arthritis.
    Ribbens C; Andre B; Jaspar JM; Kaye O; Kaiser MJ; De Groote D; Malaise MG
    J Rheumatol; 2000 Apr; 27(4):888-93. PubMed ID: 10782811
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased levels of interleukin-33 associated with bone erosion and interstitial lung diseases in patients with rheumatoid arthritis.
    Xiangyang Z; Lutian Y; Lin Z; Liping X; Hui S; Jing L
    Cytokine; 2012 Apr; 58(1):6-9. PubMed ID: 22239947
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Blood serum levels of amino-terminal pro-C-type natriuretic peptide in patients with systemic sclerosis.
    Olewicz-Gawlik A; Danczak-Pazdrowska A; Klama K; Silny W; Prokop J; Mackiewicz S; Grala P; Hrycaj P
    Connect Tissue Res; 2010 Apr; 51(2):83-7. PubMed ID: 20001845
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The association of serum matrix metalloproteinases and their tissue inhibitor levels with scleroderma disease severity.
    Toubi E; Kessel A; Grushko G; Sabo E; Rozenbaum M; Rosner I
    Clin Exp Rheumatol; 2002; 20(2):221-4. PubMed ID: 12051403
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes.
    Matsushita T; Hasegawa M; Yanaba K; Kodera M; Takehara K; Sato S
    Arthritis Rheum; 2006 Jan; 54(1):192-201. PubMed ID: 16385515
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased cutaneous T-cell-attracting chemokine levels in sera from patients with systemic sclerosis.
    Hayakawa I; Hasegawa M; Matsushita T; Yanaba K; Kodera M; Komura K; Takehara K; Sato S
    Rheumatology (Oxford); 2005 Jul; 44(7):873-8. PubMed ID: 15797972
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased serum levels and tissue expression of matrix metalloproteinase-12 in patients with systemic sclerosis: correlation with severity of skin and pulmonary fibrosis and vascular damage.
    Manetti M; Guiducci S; Romano E; Bellando-Randone S; Conforti ML; Ibba-Manneschi L; Matucci-Cerinic M
    Ann Rheum Dis; 2012 Jun; 71(6):1064-72. PubMed ID: 22258486
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Levels of matrix metalloproteinase (MMP)-1 in paired sera and synovial fluids of juvenile idiopathic arthritis patients: relationship to inflammatory activity, MMP-3 and tissue inhibitor of metalloproteinases-1 in a longitudinal study.
    Peake NJ; Khawaja K; Myers A; Jones D; Cawston TE; Rowan AD; Foster HE
    Rheumatology (Oxford); 2005 Nov; 44(11):1383-9. PubMed ID: 16049050
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment.
    Ribbens C; Martin y Porras M; Franchimont N; Kaiser MJ; Jaspar JM; Damas P; Houssiau FA; Malaise MG
    Ann Rheum Dis; 2002 Feb; 61(2):161-6. PubMed ID: 11796404
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma.
    Nikkola J; Vihinen P; Vuoristo MS; Kellokumpu-Lehtinen P; Kähäri VM; Pyrhönen S
    Clin Cancer Res; 2005 Jul; 11(14):5158-66. PubMed ID: 16033831
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Elevated circulating TWEAK levels in systemic sclerosis: association with lower frequency of pulmonary fibrosis.
    Yanaba K; Yoshizaki A; Muroi E; Hara T; Ogawa F; Usui A; Hasegawa M; Fujimoto M; Takehara K; Sato S
    J Rheumatol; 2009 Aug; 36(8):1657-62. PubMed ID: 19531747
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of simvastatin withdrawal on serum matrix metalloproteinases in hypercholesterolaemic patients.
    Huang CY; Wu TC; Lin WT; Leu HB; Lin CP; Lin SJ; Chen JW
    Eur J Clin Invest; 2006 Feb; 36(2):76-84. PubMed ID: 16436088
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Urinary type II collagen helical peptide (HELIX-II) as a new biochemical marker of cartilage degradation in patients with osteoarthritis and rheumatoid arthritis.
    Charni N; Juillet F; Garnero P
    Arthritis Rheum; 2005 Apr; 52(4):1081-90. PubMed ID: 15818703
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.